Sanofi to acquire Translate Bio for $3.2B to boost mRNA technology
Under the terms of the agreement, Sanofi will commence a cash tender offer to acquire all outstanding shares of TBIO for $38.00/share, which is expected to commence later this month.
REPORT AND RECOMMENDATIONS re 11 Motion to Dismiss for Failure to State a Claim Under Fed. R. Civ. P. 12(B)(6) filed by Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals PLC., 19 Motion to Dismiss for Failure to State a Claim filed by Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals PLC., and 30 Motion to Dismiss filed by Health Net, LLC. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than ten (10) pages) and the Response to the Objections (no longer than ten (10) pages). No further briefing shall be permitted with respect to objections without leave of the Court. (*Objections to R&R due by 8/17/2021). Signed by Judge Jennifer L. Hall on 8/3/2021. (ceg) (Entered: 08/03/2021)
Main Doc
65
Aug 3, 2021
MEMORANDUM ORDER: Defendant Health Net's Motion to Sever (D.I. 32 ) is DENIED. (*See Order for details). Signed by Judge Jennifer L. Hall on 8/3/2021. (ceg) (Entered: 08/03/2021)
